Biotek-snakken — December 2020
-
enig i 3 mdr er nada - men folk reagerer alligevel nervøst
-
Myovant Sciences and Pfizer Announce Collaboration on Relugolix in Oncology and Women’s Health. 650MUSD upfront og
4.2 BUSD mile stones. https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-and-pfizer-announce-collaboration-develop-and -
Myovant - super aftale - https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-and-pfizer-announce-collaboration-develop-and - Stiger +23% i pre market
-
It is no surprise that the market trades the stock down on today’s news, currently in the range – 5-10%. Delays and uncertainties do seldom appeal to investors. Based on what we know today, our stance is that this news is about FDA needs sufficient time to review the NDA and that a decision will come on June 17 at the latest.
-
When delays occur, it is relevant to emphasize exclusivity protection. Arimoclomol in NPC has Orphan Drug Designation. From approval, it entitles to seven years of market exclusivity in the US and ten years of market exclusivity in the EU. Orphazyme also has a method of use patent for arimoclomol in NPC that expires in 2029, with a potential extension to 2032 (US) and 2034 (EU).
kunne ikke finde på at presse nogen Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind